FDA Warns Fresenius Medical Care Over Leaking Dialysis Bags and Manufacturing Control Failures

🚨 FDA Warning Letter to Fresenius Medical Care – Major CGMP Violations

The U.S. FDA has issued a warning letter to Fresenius Medical Care over significant Current Good Manufacturing Practice (CGMP) deficiencies at its Ogden, Utah manufacturing facility.

📅 Inspection & Warning Letter

• 🏭 Facility: Fresenius USA Manufacturing, Inc. / Fresenius Medical Care North America – Ogden Plant
• 📍 Location: Ogden, Utah, USA
• 🔍 FDA Inspection: March 2–6, 2026
• 📄 Warning Letter: August 25, 2026
• ⚠️ FDA concluded that the facility’s manufacturing methods, facilities and controls did not comply with CGMP requirements.
• 💊 FDA therefore considered affected drug products adulterated under the Federal Food, Drug, and Cosmetic Act.

🩸 1. Leaking Dialysis Solution Bags

One of the most serious findings involved leaking large-volume parenteral (LVP) bags, including DELFLEX Peritoneal Dialysis Solution.

FDA noted that:

• Fresenius identified a trend of leaking bags in August 2025.
• The investigation documented 35 complaints involving approximately 156 bags from multiple batches.
• The leaks were attributed to holes created during the printing process.
• The company’s risk assessment identified peritonitis as a potential patient harm but ultimately classified the potential harm at the lowest severity level as property damage.
• FDA considered this risk assessment inadequate because leaking bags could compromise sterility.
• A voluntary recall was subsequently conducted in April 2026 for affected DELFLEX Dextrose Peritoneal Dialysis Solution products.

⚠️ Patient safety concern: A leaking peritoneal dialysis solution bag can potentially expose patients to a non-sterile product, increasing the risk of peritonitis, which can become serious or life-threatening.

FDA also noted that two previous Field Alert Reports involved leaking LVP bags associated with microbial contamination.

🔬 2. FDA Demands Independent Investigation & CAPA

FDA said Fresenius had not provided an adequate Corrective and Preventive Action (CAPA) plan.

The agency requested an independent assessment covering:

• Root causes of bag leakage
• Printing technology and equipment
• Equipment handling
• Personnel practices
• Alternative printing technologies
• Quality-unit effectiveness
• Investigation systems
• Defect rates
• Process capability
• Statistical process controls
• Equipment qualification
• Validation and maintenance programs

👁️ 3. Problems With Visual Inspection Program

FDA also identified deficiencies in the visual inspection qualification program for sterile injectable products.

Inspectors found that:

• Personnel performing visual inspections were not adequately qualified.
• Qualification kits did not contain sufficiently representative visible particles.
• Particle sizes were not adequately represented.
• Qualification records lacked sufficient detail.
• FDA noted that particles in the 100–150 micron range should typically be included to challenge detection capabilities.
• FDA requested alignment with USP <790> Visible Particulates in Injections.

👨‍🔬 4. CGMP Consultant Recommended

Because of the seriousness of the findings, FDA recommended that Fresenius hire a qualified CGMP consultant.

The consultant is expected to conduct a comprehensive six-system CGMP audit and evaluate whether corrective and preventive actions have been properly implemented and are effective.

⏰ FDA Response Requirement

Fresenius was instructed to respond within 15 working days of receiving the warning letter.

The response must explain:

1. Corrective actions already completed.
2. Corrective actions planned.
3. Measures to prevent recurrence.
4. Effectiveness of the implemented CAPA.

⚖️ Possible Regulatory Consequences

FDA warned that failure to adequately address the violations could result in further regulatory or legal action, including:

• ⚠️ Seizure
• ⚖️ Injunction
• 🚫 Potential withholding of approval for certain new applications or supplements listing the facility as a manufacturer

📌 Key Takeaway

The major concern is not simply the presence of leaking bags—it is the combination of potential sterility failures, inadequate risk assessment, deficiencies in investigations/CAPA, and weaknesses in visual inspection qualification. FDA is therefore requiring a much broader evaluation of Fresenius’ manufacturing and quality systems.